Virginia Mason Medical Center, Digestive Diseases Institute, Seattle, WA, USA.
Department of Gastroenterology and Hepatology, Kansas City VA Medical Center, Kansas City, USA.
Surg Endosc. 2020 Jul;34(7):2866-2877. doi: 10.1007/s00464-020-07484-w. Epub 2020 Mar 5.
Endoscopic ultrasound-guided choledochoduodenostomy (CDD) is emerging as an alternative technique for biliary drainage in patients who fail conventional endoscopic retrograde cholangiopancreatography (ERCP). The lumen-apposing metal stents (LAMS) are being increasingly used for CDD. We performed a systematic review and meta-analysis to evaluate the effectiveness and safety of CDD using LAMS.
We performed a systematic search of multiple databases through May 2019 to identify studies on CDD using covered self-expanding metal stents. Pooled rates of technical success, clinical success, adverse events, and recurrent jaundice associated with CDD using LAMS were estimated. A subgroup analysis was performed based on use of LAMS with electrocautery-enhanced delivery system (EC-LAMS).
Seven studies on CDD using LAMS (with 284 patients) were included in the meta-analysis. Pooled rates of technical and clinical success (per-protocol analysis) were 95.7% (95% CI 93.2-98.1) and 95.9% (95% CI 92.8-98.9), respectively. Pooled rate of post-procedure adverse events was 5.2% (95% CI 2.6-7.9). Pooled rate of recurrent jaundice was 8.7% (95% CI 4.5-12.8). On subgroup analysis of CDD using EC-LAMS (5 studies with 201 patients), the pooled rates of technical and clinical success (per-protocol analysis) were 93.8% (95% CI 90.4-97.1) and 95.9% (95% CI 91.9-99.9), respectively. Pooled rate of post-procedure adverse events was 5.6% (95% CI 1.7-9.5). Pooled rate of recurrent jaundice was 11.3% (95% CI 6.9-15.7). Heterogeneity (I) was low to moderate in the analyses.
CDD using LAMS/EC-LAMS is an effective and safe technique for biliary decompression in patients who failed ERCP. Further studies are needed to assess CDD using LAMS as primary treatment modality for biliary obstruction.
内镜超声引导下胆肠吻合术(CDD)作为一种替代技术,正在为那些无法进行常规内镜逆行胰胆管造影术(ERCP)的患者提供胆道引流。腔内置入式金属支架(LAMS)越来越多地用于 CDD。我们进行了一项系统评价和荟萃分析,以评估使用 LAMS 进行 CDD 的有效性和安全性。
我们通过系统搜索多个数据库,检索截止到 2019 年 5 月的有关使用覆盖自膨式金属支架进行 CDD 的研究。汇总使用 LAMS 进行 CDD 的技术成功率、临床成功率、不良事件和复发性黄疸的发生率。并根据使用电烧增强输送系统(EC-LAMS)进行了亚组分析。
纳入了 7 项使用 LAMS 进行 CDD 的研究(共 284 例患者),进行荟萃分析。根据意向性治疗分析,技术成功率和临床成功率(分别为 95.7%(95%CI 93.2-98.1)和 95.9%(95%CI 92.8-98.9)。术后不良事件发生率为 5.2%(95%CI 2.6-7.9)。复发性黄疸的发生率为 8.7%(95%CI 4.5-12.8)。对使用 EC-LAMS 进行 CDD 的亚组分析(5 项研究,201 例患者),技术成功率和临床成功率(意向性治疗分析)分别为 93.8%(95%CI 90.4-97.1)和 95.9%(95%CI 91.9-99.9)。术后不良事件发生率为 5.6%(95%CI 1.7-9.5)。复发性黄疸的发生率为 11.3%(95%CI 6.9-15.7)。分析中异质性(I)为低至中度。
对于 ERCP 失败的患者,使用 LAMS/EC-LAMS 进行 CDD 是一种有效的胆道减压技术。需要进一步研究来评估使用 LAMS 作为胆道梗阻的主要治疗方法进行 CDD。